Taizhou pharma firm expands global partnerships with advanced drug delivery platform

Overseas Pharmaceuticals in China Medical City, Taizhou. [Photo/WeChat account: weigg6666]

Overseas Pharmaceuticals, based in China Medical City, Taizhou, has entered strategic partnerships with two major multinational drugmakers in Europe and South America to jointly develop controlled-release medicines for global markets, marking a shift from product exports to technology-driven collaboration.

Overseas Pharmaceuticals will work with its international partners using its proprietary sustained and controlled-release technology platform, which allows drugs to release active ingredients in precise stages to improve effectiveness and reduce side effects.

"This time, our partners are seeking our technology platform itself, not just a specific product," said Cai Huaihan, head of international business development. "It reflects recognition of our innovation capabilities."

Products developed by Overseas Pharmaceuticals. [Photo/WeChat account: weigg6666]

The company's platform holds 23 invention patents across China, Europe, the United States, and Japan. Using this technology, it has developed 30 new drug candidates that have received approval for clinical trials from China's drug regulator. In recent years, its projects have accounted for more than 40 percent of China's approved modified-release innovative drugs, addressing major conditions such as hypertension, diabetes, chronic heart failure, pain, and neurological disorders.

Under the partnership model, overseas partners will primarily handle clinical development and commercialization, while the Taizhou-based company provides core technology and research support. Both sides will share risks and future returns.

The company plans to strengthen its international team, expand global intellectual property protection, and enhance project management capabilities, aiming to build long-term competitiveness as a technology-driven player in the global pharmaceutical industry.